Novartis Exjade OK'd in US for non-transfusion-dependent thalassemia
This article was originally published in Scrip
Executive Summary
The US FDA on 23 January granted an accelerated approval to Novartis to expand the indication for its chelation therapy Exjade (deferasirox) as a therapy for chronic iron overload in patients 10 years or older with non-transfusion-dependent thalassemia (NTDT), a group of genetic blood disorders that cause anemia.